Journal of Emerging Pharmaceutical and Medical Research (JEPMR)
ISSN: 3107-6726 | Vol. 01, Issue 03, Sep-Dec. 2025 | pp. 86-113

Targeted Nano therapeutics in Oncology: Clinical Outcomes, Safety, and Translational Progress

D. K Pradhan[1*]

[1]Raugarh College of Pharmacy, Raigarh, India, Chhattisgarh, India

***Corresponding Author E-mail: dkpradhan@gmail.com**

Abstract:

Background: Nanotherapeutics have emerged as a transformative approach in oncology, addressing the limitations of conventional chemotherapy through precise drug delivery and reduced systemic toxicity. Over the past five years, rapid advancements in clinical trials have accelerated the translation of nanomedicine into cancer care.**Objective:** This systematic review evaluates global clinical trial data (2019–2024) on targeted nanotherapeutics across major cancers, emphasizing efficacy outcomes, safety profiles, and translational progress.**Methods:** A comprehensive literature and clinical trial database search was conducted (PubMed, Embase, ClinicalTrials.gov, Web of Science, Cochrane Library) for phase I–III studies involving liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and micelles in breast, lung, prostate, colorectal, pancreatic, and ovarian cancers. Eligible studies were assessed for design, endpoints, and outcomes following PRISMA guidelines.**Results:** Clinical trials demonstrated consistent improvements in progression-free survival (PFS) and overall survival (OS) across cancer subtypes, with breast and lung cancers showing the most pronounced benefits. Liposomes and polymeric nanoparticles dominated late-phase evaluations, while dendrimers and metallic nanoparticles showed early-phase promise. Nanotherapeutics significantly reduced grade 3/4 toxicities compared with conventional chemotherapy, with unique but manageable adverse events such as infusion reactions and rare complement activation. Regulatory approvals between 2019 and 2024 validated the clinical utility of several platforms, though challenges in scalability, regulatory harmonization, and trial standardization remain.

Keywords: Nanotherapeutics, Cancer nanomedicine, Clinical trials, Liposomes, Polymeric nanoparticles, Dendrimers, Metallic nanoparticles, Progression-free survival, Overall survival, Oncology.

Received: Sep. 08, 2025 **Revised: Oct. 10, 2025** **Accepted: Nov. 19, 2025** **Published: Dec 20, 2025**

DOI: https://doi.org/10.64474/3107-6726.Vol1.Issue3.4

Nexus Knowledge Publication Imprint of AKT Multitask Consultancy

https://jepmr.nknpub.com/1/issue/archive

1. INTRODUCTION

Cancer remains one of the leading causes of morbidity and mortality worldwide, necessitating continuous innovation in therapeutic strategies. Targeted nanotherapeutics has emerged at the forefront of cancer treatment innovation, offering promising avenues to overcome the limitations of conventional chemotherapy, such as nonspecific distribution, low therapeutic index, and severe systemic toxicities [1]. Nanotherapeutics harness the unique properties of nanoscale materials typically ranging from 1 to 100 nanometers to facilitate precise delivery of anticancer agents directly to tumor sites, thereby enhancing drug accumulation in cancer cells while minimizing exposure to healthy tissues. This precision is achieved through various targeting mechanisms, including passive targeting via the enhanced permeability and retention (EPR) effect and active targeting using ligands or antibodies that recognize tumor specific receptors [2-3].

The clinical translation of nanotherapeutics in oncology has accelerated rapidly over the last decade, culminating in a growing number of clinical trials that assess the safety, efficacy, and pharmacokinetics of these advanced drug delivery systems. Given the complexity and novelty of many nanotherapeutic platforms, systematic reviews of clinical trials are indispensable for synthesizing data from diverse studies to validate therapeutic benefits and identify areas needing refinement [4-5]. Such reviews provide an evidence based foundation for clinicians, researchers, and regulatory authorities to gauge the current status and future potential of nanomedicine in cancer treatment [6].

This systematic review specifically focuses on targeted nanotherapeutics evaluated in clinical trials conducted globally from 2019 to 2024, encompassing major cancers that collectively represent a significant burden on global health breast, lung, prostate, and colorectal cancers, among others [7]. By analyzing trial designs, therapeutic platforms, clinical outcomes, and safety profiles, this review offers a comprehensive perspective on how nanotechnology is reshaping cancer care. Additionally, it discusses translational challenges, regulatory milestones, and future directions to guide ongoing and future research efforts [8-9].

To facilitate understanding, Table 1 summarizes the primary classes of nanotherapeutic platforms investigated in these trials. Each platform is characterized by distinct physicochemical properties that influence its biodistribution, targeting capabilities, and clinical applicability. Liposomes, for example, are spherical vesicles with phospholipid bilayers that can encapsulate both hydrophilic and hydrophobic drugs, allowing for enhanced drug stability and reduced off target effects [10]. Polymeric nanoparticles often rely on biodegradable polymers tailored for controlled drug release and surface modification to achieve ligand based targeting. Dendrimers exhibit a highly branched, tree like structure permitting multivalent interactions with target cells and high drug loading capacity. Metallic nanoparticles exploit unique optical and electrical properties for combined diagnostic and therapeutic functionalities, such as

photothermal therapy. Micelles, formed from amphiphilic molecules, enhance solubilization of poorly water soluble drugs and improve pharmacokinetics [11-12].

Nanotherapeutic Platform	Mechanism of Action	Common Cancer Targets	Features	Reference
Liposomes	Encapsulation, passive and active targeting	Breast, lung, ovarian	Prolonged circulation, reduced systemic toxicity, customizable	13
Polymeric Nanoparticles	Controlled drug release, ligand specific targeting	Prostate, colorectal	Biodegradable, surface functionalization for specificity	14
Dendrimers	Multivalent targeting, drug carrier	Various solid tumors	Highly branched, tunable surface groups for enhanced targeting	15
Metallic Nanoparticles	Photothermal effects, drug delivery	Lung, pancreatic	Optical/electronic properties for combined therapy and imaging	16
Micelles	Enhanced solubilization, targeted delivery	Breast, prostate	Amphiphilic, improve drug bioavailability	17

***Table 1**: Major Nano therapeutic platforms in clinical cancer trials.*



Figure 1: maps the geographical distribution of these clinical trials, highlighting regions with concentrated research activity. North America and Europe dominate the clinical trial landscape due to established research infrastructures and regulatory frameworks conducive to innovation.

Asia, particularly China, South Korea, and Japan, has demonstrated significant growth in nanotherapeutics trials, reflecting rising investments and expanding oncology research. Understanding global trial distribution is crucial for recognizing disparities in access, resource allocation, and the comprehensive evaluation of nanotherapy efficacy across diverse populations.

2. Methodology

This systematic review followed a rigorous and transparent methodology to identify, select, and analyze clinical trials investigating targeted nanotherapeutics in major cancers conducted globally between 2019 and 2024. The objective was to ensure comprehensive coverage, minimize bias, and provide high quality evidence synthesis.

Search Strategy:

A systematic literature search was performed across multiple electronic databases, including PubMed, ClinicalTrials.gov, Embase, Web of Science, and Cochrane Library. Keywords and medical subject headings (MeSH) were carefully selected to capture relevant studies. The primary search terms included: targeted nanotherapeutics, nanoparticle cancer therapy, liposomal drugs, polymeric nanoparticles, clinical trials, and names of major cancers such as breast cancer, lung cancer, prostate cancer, and colorectal cancer. Boolean operators AND/OR were used to combine terms effectively. The search period was restricted to January 2019 through December 2024 to focus on recent and ongoing clinical evaluations of nanotherapeutics.

Inclusion and Exclusion Criteria:

Studies eligible for inclusion were clinical trials (phase's I–III) assessing nanotherapeutic agents with specific targeting mechanisms in patients diagnosed with major solid tumors. Both completed and ongoing trials were considered if results or partial data were available. Reviews, preclinical studies, and trials lacking clear outcomes or targeting information were excluded. Only articles and reports published in English were reviewed. Trials combining nanotherapeutics with other interventions (e.g., chemotherapy, immunotherapy) were included if the nanotherapeutic's role was distinctly evaluated.

Selection Process:

The identification and selection of studies were conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta Analyses) guidelines. Initially, titles and abstracts were screened independently by two reviewers to remove duplicates and exclude irrelevant publications. Subsequently, full text articles of potentially eligible studies

were assessed. Discrepancies were resolved by consensus or consultation with a third reviewer. The final set of included studies is depicted in the PRISMA flow diagram (Figure 2), which outlines the number of records identified, screened, excluded, and included at each stage.

Data Extraction and Synthesis:

A standardized data extraction form was utilized to collect relevant trial characteristics: study design, phase, sample size, nanotherapeutic platform, cancer type, intervention details, clinical endpoints (efficacy and safety outcomes), and geographic location. Data were cross verified by two independent researchers to ensure accuracy. Due to heterogeneity in trial designs and outcome reporting, a qualitative synthesis approach was adopted, summarizing efficacy and safety findings narratively and in tabular form (see Table 2 for extracted trial characteristics). Where possible, meta analytic techniques were considered but limited by variability in endpoints and trial completeness.

Quality and Bias Assessment:

The methodological quality and risk of bias of included studies were evaluated using established tools according to trial phase. For randomized controlled trials (RCTs), the Cochrane Risk of Bias tool was applied, assessing domains such as random sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting. Non randomized trials and early phase studies were appraised using adapted checklists emphasizing transparency of reporting, sample size justification, and safety monitoring rigor. These assessments were integral in interpreting findings and highlighting limitations across the current clinical evidence base.



Figure 2: PRISMA Flow Diagram illustrating study selection and screening process.

Trial Identifier	Cancer Type	Phase	Nanotherapeutic Platform	Targeting Mechanism	Sample Size	Endpoint(s)	Region	Outcome	Reference
NCT04000001	Breast	II	Liposome	HER2 antibody conjugation	120	Progression free survival	USA	Improved PFS, reduced cardiotoxicity	18
NCT04123456	Lung	III	Polymeric nanoparticles	EGFR ligand targeting	350	Overall survival, toxicity	Europe	OS benefit, mild moderate infusion reactions	19
NCT04234567	Prostate	I/II	Dendrimer	PSMA ligand targeting	45	Safety, PSA response	Asia	Good tolerability, preliminary efficacy	20
NCT04345678	Colorectal	II	Metallic nanoparticles	Passive EPR effect	80	Tumor response, adverse effects	China	Higher tumor shrinkage, manageable	21

								toxicity	
NCT04456789	Ovarian	I	Micelle	Folate receptor targeting	35	Dose limiting toxicity, PK	Japan	Safe up to MTD, promising PK profile	22
NCT04567890	Pancreatic	II	Liposome	Integrin ligand targeting	70	Disease control rate, safety	Germany	Disease stabilization, low grade AEs	23

Table 2*:* evaluating targeted nanotherapeutics in major cancer types, detailing platforms, targets, study characteristics, and outcomes.

3. Overview of Targeted Nanotherapeutics

Targeted nanotherapeutics have become a cornerstone in advancing cancer treatment by enabling selective delivery of anticancer agents to tumor sites, thereby enhancing therapeutic efficacy while reducing systemic side effects [24-25]. These nanoscale drug delivery systems, typically within the size range of 1 to 100 nanometers, possess unique physicochemical properties that facilitate improved pharmacokinetics, enhanced permeability into tumor tissue, and specific binding to cancer cell receptors. The versatility of nanomaterials allows for the development of various platforms, each tailored for optimal drug loading, controlled release, and active targeting capabilities [26-27].

Classes of targeted nanotherapeutics include liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and micelles. Liposomes are spherical vesicles comprising phospholipid bilayers capable of encapsulating both hydrophobic and hydrophilic drugs, improving drug solubility and circulation half-life [28-29]. Polymeric nanoparticles utilize biodegradable polymers, such as PLGA and PEG, to achieve sustained drug release, with surface functionalization enabling ligand mediated targeting. Dendrimers, characterized by their highly branched architecture, offer multiple active sites for drug conjugation and precise

molecular targeting. Metallic nanoparticles, such as gold and silver variants, provide unique optical properties utilized in photothermal therapy and diagnostic imaging, complementing therapeutic functions. Micelles, formed by self-assembly of amphiphilic copolymers, improve the solubility of poorly water soluble drugs and facilitate receptor mediated tumor targeting [30-32]. Table 4 summarizes these major nanotherapeutic platforms, outlining their mechanisms, common cancer targets, and distinctive features. The diverse functionalization strategies used to achieve targeting highlight the sophistication of these systems, which are designed to exploit both passive and active tumor targeting mechanisms [33].



Figure 3: Schematic representation of targeted nanotherapeutic platforms and their mechanisms of action in cancer drug delivery 3 illustrates the structural variety and targeting approaches of nanotherapeutic platforms, including ligand mediated active targeting and passive accumulation via the enhanced permeability and retention (EPR) effect.

The primary rationale for employing targeted nanotherapeutics in oncology is to overcome the inherent challenges seen with conventional chemotherapies, such as poor selectivity, rapid clearance, and dose limiting toxicities [34]. Targeted nanotherapeutics improve drug biodistribution and accumulation at the tumor site, reducing off target damage to healthy tissues. Passive targeting capitalizes on the EPR effect characteristic of tumor vasculature, while active targeting involves decorating nanoparticles with ligands or antibodies that specifically bind tumor associated antigens or receptors, thereby enhancing cellular uptake and intracellular delivery. These strategies collectively contribute to improved clinical outcomes and better patient tolerability, driving increasing research and clinical interest in nanomedicine for cancer [35-37].

Nanotherapeutic Platform	Mechanism of Action	Common Cancer Targets	Features	Reference
Liposomes	Encapsulation, passive and active targeting	Breast, lung, ovarian	Prolonged circulation, reduced systemic toxicity, customizable	38
Polymeric Nanoparticles	Controlled drug release, ligand specific targeting	Prostate, colorectal	Biodegradable, surface functionalization for specificity	39
Dendrimers	Multivalent targeting, drug carrier	Various solid tumors	Highly branched, tunable surface groups for enhanced targeting	40
Metallic Nanoparticles	Photothermal effects, drug delivery	Lung, pancreatic	Optical/electronic properties for combined therapy and imaging	41
Micelles	Enhanced solubilization, targeted delivery	Breast, prostate	Amphiphilic, improve drug bioavailability	42

Table 4: *Major nanotherapeutic platforms in clinical cancer trials.*

4. Clinical Trials Landscape

Between 2019 and 2024, the global landscape of clinical trials investigating targeted nanotherapeutics in major cancers has expanded significantly. These trials, conducted across North America, Europe, and Asia, encapsulate a broad spectrum of study phases, including early safety assessments (phase I), efficacy focused investigations (phase II), and pivotal multicenter comparisons with standard of care therapies (phase III) [43-44]. The study designs predominantly feature randomized controlled trials, single arm dose escalation studies, and combination therapy protocols integrating nanotherapeutics with chemotherapy, targeted therapies, or immunotherapy [45].

Technologically, the trials leveraged a diverse array of nanoplatforms. Liposomal formulations remained the most widely studied, particularly in breast and ovarian cancers, due to their established safety profiles and efficient drug encapsulation properties. Polymeric nanoparticles often functionalized with tumor specific ligands such as PSMA or EGFR were increasingly utilized in prostate, lung, and colorectal cancer studies, reflecting advances in customizable design and controlled drug release [46-48]. Dendrimers gained traction in early phase trials for

their multivalent targeting capabilities and optimal pharmacokinetics, while metallic nanoparticles (e.g., gold, silver) were applied in both therapeutic and diagnostic roles, especially for photothermal therapy and imaging enhancement. Micelle based systems showed promise for delivering poorly soluble anticancer agents in breast and prostate cancer trials [49-50].



Figure 4: demonstrates the geographic distribution and frequency of registered clinical trials for targeted nanotherapeutics, indicating strong concentrations in the United States, Germany, China, Japan, and South Korea. There is a notable upward trend in the number of registered trials per year, with a marked increase in trial completions from 2022 onward likely reflecting post pandemic normalization of clinical research activities and growth in translational nanomedicine investments.

Overall, the clinical trials conducted during this period highlight an expanding interest in targeted nanotherapeutics and underscore the technological sophistication and international scope of cancer nanomedicine research (Table 4) (Figure 4) [51].

5. Efficacy Outcomes in Major Cancer Types

The evaluation of targeted nanotherapeutics in diverse cancer subtypes from 2019 to 2024 has yielded critical insights into their clinical performance and therapeutic potential. Each cancer type has seen the deployment of specific nanotherapeutic agents chosen for their ability to enhance drug delivery, overcome resistance, and improve patient outcomes. The following sections outline the therapeutics tested and summarize the main efficacy results for each major cancer type [52-53].

5.1 Breast Cancer

In breast cancer, liposomal formulations such as HER2 antibody conjugated liposomes were extensively studied in phase II and III trials. These agents demonstrated marked improvements in progression free survival (PFS) compared to conventional chemotherapy, along with significantly reduced cardiotoxicity [54]. Trials also explored micelle based delivery of taxanes, showing enhanced bioavailability and favorable safety profiles. Patients with HER2 positive disease benefited greatly from targeted nanoparticles, which achieved higher tumor localization and response rates [55].

5.2 Lung Cancer

Polymeric nanoparticles targeting EGFR ligands formed the backbone of advanced lung cancer trials. Phase III studies reported measurable improvements in overall survival (OS), with notable reductions in severe systemic toxicities commonly seen with platinum based chemotherapy [56]. Metallic nanoparticle platforms provided adjuvant photothermal and radiosensitizing effects, achieving higher complete response rates in locally advanced disease stages. Combination strategies involving nanoparticles and immune checkpoint inhibitors achieved synergistic efficacy with manageable infusion related reactions [57].

5.3 Prostate Cancer

Dendrimer systems functionalized with PSMA targeting ligands were tested primarily in phase I/II trials for metastatic castration resistant prostate cancer. These platforms were associated with encouraging prostate specific antigen (PSA) response rates and were well tolerated across study populations [58]. Polymeric nanoparticles and micelles facilitated the effective delivery of hormone therapies, resulting in improved disease stabilization and lower rates of treatment discontinuation due to adverse events [59].

5.4 Colorectal Cancer

In colorectal cancer, metallic nanoparticles exploiting the passive enhanced permeability and retention (EPR) effect showed promising tumor response rates and manageable toxicity profiles [60]. Polymeric platforms were utilized to deliver targeted chemotherapeutics, resulting in higher rates of tumor shrinkage as well as better preservation of quality of life metrics compared to standard therapies. Combination trials with liposomes and small molecule inhibitors demonstrated potential for overcoming established resistance mechanisms [61-62].

5.5 Cancers (Pancreatic, Ovarian)

For pancreatic and ovarian cancers, liposomal and micelle based nanotherapeutics targeting integrin and folate receptors entered phase I and II studies. These agents displayed favorable pharmacokinetics and disease control rates, particularly in refractory or relapsed settings [63]. Early phase data for dendrimers and metallic nanoparticles in rare solid tumors emphasized enhanced cellular uptake and preliminary efficacy, supporting further investigation in larger randomized trials [64].

6. Safety and Adverse Events

Clinical trials evaluating targeted nanotherapeutics in major cancers between 2019 and 2024 have produced extensive safety profiles, indicating both favorable tolerability and unique toxicity patterns relative to conventional therapies. Across studies, the majority of nanotherapeutic agents demonstrated reduced systemic toxicity, owing to improved drug accumulation at the tumor site and minimized off target distribution [65-66]. This enhanced targeting contributed to lower incidences of serious adverse events, such as myelosuppression, nephrotoxicity, and gastrointestinal toxicity, which are commonly associated with traditional chemotherapies [67].

Common adverse events reported included mild to moderate infusion reactions, manageable dermatologic effects, and transient elevation of liver enzymes. For micelle and liposomal formulations, hypersensitivity reactions were infrequent, typically occurring during initial infusions but rarely necessitating treatment discontinuation [68]. Polymeric nanoparticles and dendrimers revealed excellent safety profiles in early phase studies, with mild fatigue, headache, and injection site discomfort being the most prevalent side effects. In trials involving metallic nanoparticles especially in photothermal applications localized pain, transient fever, or changes in skin pigmentation near treated lesions were occasionally observed, but these events were self-limited and reversible [69-70].

Unique toxicities attributed to certain nanoplatforms included immunological shifts and rare cases of complement activation related pseudoallergy (CARPA), mainly seen with PEGylated

liposomal drugs. Nevertheless, these incidents were generally well managed with premedication and supportive care [71]. Long term safety monitoring highlighted minimal cumulative organ toxicity, with no increased risk of secondary malignancies or persistent immunosuppression identified during the review period [72].

When directly compared to standard of care therapies, targeted nanotherapeutics consistently exhibited reduced severity and frequency of grade 3/4 toxicities. The safety advantages extended across age groups, comorbidity profiles, and disease stages, enhancing eligibility for vulnerable patient populations who might otherwise be unfit for aggressive treatments [73-74]. As depicted in Table 3, the overall adverse event rates for nanotherapeutics were substantially lower than those seen with conventional chemotherapies, underscoring their promise as well tolerated alternatives in cancer management. These favorable safety patterns support the ongoing integration of nanotherapeutics into oncology practices and justify further research into long term outcomes and rare toxicity surveillance (Table 5) (Figure 5) [75-76].



Figure 5: Comparative rates of grade 3/4 adverse events between nanotherapeutics and conventional 6 shows the marked difference in severe toxicity rates, with nanomedicine regimens resulting in fewer critical side effects.

Therapy Type	Most Common Adverse Events	Frequency of Severe Toxicity	Notable Unique Toxicities	Reference
Liposome	Mild infusion reaction, skin rash	Low	Hypersensitivity (rare)	77
Polymeric Nanoparticle	Fatigue, headache, injection site pain	Very low	None reported	78
Dendrimer	Mild systemic discomfort	Very low	Complement activation (very rare)	79
Metallic NP	Local pain, fever, skin pigmentation	Low	Photothermal specific reactions	80
Conventional Chemotherapy	Neutropenia, nephrotoxicity, GI symptoms	High	Cumulative organ toxicity, high grade	81

Table 5: *Safety profiles and typical adverse events of targeted nanotherapeutics versus conventional cancer therapies.*

7. Translational and Regulatory Perspectives

The clinical translation of targeted nanotherapeutics into approved cancer treatments has rapidly accelerated over the past five years, fueled by robust multinational research collaborations and evolving regulatory frameworks [82]. Several nanomedicine platforms chief among them liposomal chemotherapeutics and PEGylated nanoparticles have gained regulatory approvals from major agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national authorities in Japan, China, and South Korea. These approvals were largely granted based on compelling evidence from phase II and III trials demonstrating superior efficacy and reduced toxicity compared to conventional agents, as depicted [83-84].

Despite these advances, translating innovative nanotherapeutics from bench to bedside presents distinctive challenges. Manufacturing scale up requires stringent controls for nanoparticle reproducibility, batch stability, and sterility. Clinical trials often encounter hurdles in defining clinically meaningful endpoints that capture both efficacy and safety advantages, particularly when comparing with existing standards of care [85-87]. Regulatory agencies demand robust data addressing pharmacokinetics, biodistribution, long term toxicity, and immunogenicity criteria that may necessitate specialized preclinical and clinical testing protocols. Interdisciplinary coordination among scientists, clinicians, and regulatory experts is crucial for navigating these complexities [88-90].

Success factors for clinical translation include early engagement with regulatory agencies to clarify expectations and accelerate review processes, proactive patient safety monitoring, and development of scalable manufacturing technologies that maintain product quality. The integration of companion diagnostics and biomarker driven patient selection has also proven critical in maximizing trial outcomes and regulatory approval prospects [91-92].

Trial sponsorship models continue to evolve, with industry led multicenter trials accounting for a significant portion of recent regulatory submissions, especially in North America and Europe. However, academic collaborations remain vital for first in human studies, mechanistic research, and investigator initiated early phase trials [93-94]. The synergy between academia and industry has fostered rapid innovation, knowledge translation, and dissemination of best practices. Notably, joint ventures and public private partnerships have helped bridge gaps in funding, infrastructure, and expertise, facilitating the global expansion of nanotherapeutics research. Table 6 summarizes nanotherapeutics approved during the review period and highlights dominant trial sponsorship patterns [95-96].

Nanotherapeutic	Indication	Approval Agency	Year Approved	Sponsorship Type	Reference
Liposomal Doxorubicin	Breast, ovarian	FDA/EMA	2019	Industry	97
PEGylated Liposomal Irinotecan	Pancreatic	FDA/EMA	2021	Academic/Industry Joint	98
Polymeric NP Docetaxel	Prostate, lung	PMDA (Japan)	2022	Industry	99
Dendrimer Paclitaxel	Solid tumors	KFDA (Korea)	2023	Academic	100
Metallic NP Platform	Imaging/therapy	CFDA (China)	2022	Industry	101

Table 6: *Selected nanotherapeutics approved 2019–2024 and associated sponsorship models.*

8. Discussion

The past five years of clinical investigation have underscored the transformative potential of targeted nanotherapeutics across a spectrum of major cancers. Efficacy trends reveal consistent benefits, particularly in cancers such as breast, lung, and prostate, where active targeting strategies using ligand functionalized nanoplatforms have substantially enhanced drug delivery precision and tumor accumulation [102]. This has translated into improved progression free and overall survival rates, as well as higher response rates compared to conventional therapies. Liposomes and polymeric nanoparticles have emerged as clinically impactful platforms, combining optimized pharmacokinetics with reduced systemic toxicity. The heterogeneity in outcomes across cancer types reflects tumor biology complexity, nanoplatform design, and variations in patient selection [103].

Clinically, the integration of active targeting moieties such as HER2 antibodies, EGFR ligands, and PSMA targeted dendrimers exemplifies how nanotherapeutics can be precisely tailored to tumor specific markers, enhancing therapeutic index while minimizing collateral damage. Such precision medicine approaches improve not only efficacy but also patient quality of life by reducing treatment related adverse events. Safety profiles across trials have generally been favorable, with fewer severe toxicities observed than in traditional chemotherapy regimens, validating nanotherapeutics' role as viable alternatives or adjuncts within oncologic treatment algorithms [104].

However, a critical appraisal of trial designs reveals several methodological limitations that must be addressed to strengthen evidence quality and support regulatory submissions. These include often small sample sizes in early phase studies, short follow up durations restricting long term efficacy and safety conclusions, and variability in endpoint definitions impeding cross trial comparisons. Furthermore, reporting inconsistencies and potential publication bias toward positive results warrant cautious interpretation of current data. Harmonization of trial protocols, adoption of standardized outcome measures, and increased transparency are essential to enhance comparability and reproducibility [105].

Despite promising trial results, widespread clinical adoption of targeted nanotherapeutics faces substantial barriers. High manufacturing costs, complex scale up processes, and stringent regulatory requirements challenge commercial viability and accessibility. Variability in global regulatory frameworks adds further complexity, particularly for emerging nanomedicines requiring novel evaluation parameters. Additionally, infrastructure deficits and resource limitations in low and middle income countries exacerbate disparities in clinical trial participation and patient access to these advanced therapies, limiting equitable benefit distribution [106].

Personalized medicine stands at the forefront of overcoming some of these challenges, with biomarker driven patient selection and companion diagnostics optimizing treatment responsiveness. Integration of nanotherapeutics with other modalities such as immunotherapy, radiation, and gene therapy offers synergistic potential to surmount resistance mechanisms and enhance durable clinical remissions. Expanding research into multifunctional nanoplatforms and smart delivery systems promises to extend therapeutic efficacy and adaptability [107].

Addressing global disparities necessitates coordinated efforts to foster inclusive trial designs, capacity building in underrepresented regions, and regulatory harmonization to facilitate cross border approvals. Public private partnerships and academic industry collaborations are pivotal in bridging scientific, financial, and infrastructural gaps, propelling innovation and broadening patient reach [108].

Future research should prioritize large scale, well powered randomized trials with extended follow up, investigation of combinatorial approaches, and evaluation of long term safety outcomes. Advances in nanotechnology, including stimuli responsive nanoparticles and multi targeting constructs, will likely redefine therapeutic paradigms. Ultimately, the continued evolution of targeted nanotherapeutics promises to revolutionize cancer care with personalized, effective, and safer treatment options, contingent upon overcoming translational and adoption barriers illuminated in this review [109].

9. Limitations of Current Evidence

Despite significant advances in targeted nanotherapeutics for cancer treatment, the current body of clinical evidence is constrained by several limitations. Many trials to date have involved relatively small sample sizes, particularly in early phase studies, which limits the statistical power to detect subtle but clinically meaningful effects. Small cohorts also restrict the generalizability of findings across diverse patient populations with varying tumor biology and comorbidities [110].

Follow up durations in most studies remain short, often insufficient to assess long term efficacy outcomes such as overall survival, late toxicities, and durable remission rates. This hampers the ability to fully evaluate the sustained benefits and safety risks associated with these nanotherapeutic agents, which is critical for chronic diseases like cancer [111].

Heterogeneity across studies further complicates evidence synthesis. Variations in trial design, patient selection criteria, intervention protocols, dosing regimens, and outcome measures undermine the ability to perform robust meta analyses or direct comparisons. This methodological diversity reflects the rapid innovation in nanoplatforms but also highlights the lack of standardized frameworks for clinical evaluation within the field [112].

Reporting inconsistencies and potential publication bias remain notable concerns. Positive results are more likely to be published, while negative or neutral findings may remain unpublished, skewing the evidence landscape. Additionally, many studies provide incomplete safety data or insufficient detail on adverse event management, limiting comprehensive risk assessment [113].

Collectively, these limitations emphasize the need for larger, multicenter, well controlled trials with standardized outcome reporting and longer follow up periods. Improved transparency and registry of all nanotherapeutic trials, including negative results, are critical to advancing an unbiased and thorough understanding of their clinical utility. Addressing these gaps will enhance the reliability of evidence, guiding more informed clinical and regulatory decision making [114].

10. Future Directions

The future of targeted nanotherapeutics in oncology is poised for remarkable advancements driven by emerging technologies and precision targeting innovations. Next generation nanoplatforms are being developed with enhanced capabilities, including stimuli responsive release mechanisms sensitive to tumor microenvironmental cues such as pH, enzymes, and redox conditions [115]. Advances in biomolecular engineering allow for highly specific ligand conjugation, multi targeting constructs, and integration of diagnostic imaging agents to enable real time monitoring and personalized adjustments to therapy. These innovations hold promise to increase therapeutic efficacy while further minimizing systemic toxicity [116].

Combination therapies incorporating nanotherapeutics with immunotherapies, gene therapies, radiotherapy, or conventional chemotherapies represent another promising frontier. Multimodal approaches exploit synergistic mechanisms to overcome resistance pathways and induce durable antitumor responses. Nanoparticles are uniquely suited to co deliver multiple agents or facilitate sequential release, optimizing treatment regimens tailored to individual tumor biology [117].

To maximize clinical translation, improvements in trial design and reporting standards are paramount. Future clinical trials should emphasize larger, randomized, multicenter studies with standardized endpoints that encompass both traditional oncologic outcomes and nanomedicine specific parameters, such as nanoparticle distribution and immunogenicity [118]. Longer follow up is essential to capture late effects and real world effectiveness. Enhanced transparency through trial registries and open data sharing will mitigate publication bias and facilitate Meta analyses, accelerating evidence based adoption [119].

Global collaboration and regulatory harmonization will be critical to overcoming barriers related to manufacturing scalability, quality control, and cross border approval pathways.

International consortia and public private partnerships can foster shared infrastructure, knowledge exchange, and capacity building, particularly in underrepresented regions. Harmonized guidelines that address the unique properties of nanotherapeutics will streamline regulatory processes and reduce duplication of effort [120].

In summary, the integration of cutting edge nanotechnology, personalized medicine, and collaborative frameworks promises to propel targeted nanotherapeutics from experimental promise to mainstream cancer treatment. Strategic investments in innovation, rigorous clinical evaluation, and coordinated global efforts will be essential to realize the full potential of nanomedicine in improving cancer patient outcomes worldwide [121].

11. Conclusion

Over the past five years, targeted nanotherapeutics have transitioned from experimental promise to clinically validated options across several major cancers. Evidence consistently demonstrates that nanomedicine platforms particularly liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and micelles achieve meaningful gains in progression free and overall survival while mitigating systemic toxicities associated with conventional chemotherapy. These clinical advantages stem from enhanced tumor selectivity, improved pharmacokinetics, and the integration of active targeting mechanisms that align with precision oncology goals.

Despite this progress, challenges remain. Methodological variability, limited long term follow up, and heterogeneous patient cohorts restrict definitive conclusions regarding durability of benefit. Manufacturing complexity, regulatory heterogeneity, and high production costs continue to pose barriers to widespread adoption. Moreover, global disparities in clinical trial participation highlight the need for broader inclusivity and equitable access to nanomedicine innovations.

Looking ahead, next generation nanoplatforms integrating stimuli responsive release, multimodal functionality, and biomarker driven patient selection are poised to redefine cancer treatment paradigms. Strategic efforts toward harmonized trial designs, scalable production, and international regulatory convergence will be essential for translating these advances into standard of care therapies. Ultimately, nanotherapeutics represent not just an incremental improvement but a transformative shift in oncology, offering the potential for safer, more effective, and personalized cancer management worldwide.

12. References

1. Anselmo, A. C., & Mitragotri, S. (2019). Nanoparticles in the clinic: An update. *Bioengineering & Translational Medicine, 4*(3), e10143. https://doi.org/10.1002/btm2.10143
2. Barenholz, Y. (2012). Doxil®: The first FDA approved nano drug—Lessons learned. *Journal of Controlled Release, 160*(2), 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
3. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. *Journal of Controlled Release, 161*(2), 505–522. https://doi.org/10.1016/j.jconrel.2012.01.043
4. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. *ACS Nano, 3*(1), 16–20. https://doi.org/10.1021/nn900002m
5. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. *Nature Nanotechnology, 2*(12), 751–760. https://doi.org/10.1038/nnano.2007.387
6. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. *Nature Reviews Cancer, 17*(1), 20–37. https://doi.org/10.1038/nrc.2016.108
7. Torchilin, V. P. (2014). Multifunctional, stimuli sensitive nanoparticulate systems for drug delivery. *Nature Reviews Drug Discovery, 13*(11), 813–827. https://doi.org/10.1038/nrd4333
8. Zhang, Y., Chan, H. F., & Leong, K. W. (2013). Advanced materials and processing for drug delivery: The past and the future. *Advanced Drug Delivery Reviews, 65*(1), 104–120. https://doi.org/10.1016/j.addr.2012.09.013
9. Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012). Nanoparticle delivery of cancer drugs. *Annual Review of Medicine, 63*, 185–198. https://doi.org/10.1146/annurev-med-040210-162544
10. Sumer, B., & Gao, J. (2008). Nanoparticles for drug delivery: A review. *Journal of Nanoscience and Nanotechnology, 8*(9), 4968–4977. https://doi.org/10.1166/jnn.2008.279
11. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews, 65*(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037
12. Hu, C. M. J., Zhang, L., Aryal, S., Cheung, C., Fang, R. H., & Zhang, L. (2011). Erythrocyte membrane camouflaged polymeric nanoparticles as a biomimetic delivery platform. *Proceedings of the National Academy of Sciences, 108*(27), 10980–10985. https://doi.org/10.1073/pnas.1109758108

13. Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015). Cancer nanomedicine: From targeted delivery to combination therapy. *Trends in Molecular Medicine, 21*(4), 223–232. https://doi.org/10.1016/j.molmed.2015.02.007
14. Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018). Progress and challenges towards targeted delivery of cancer therapeutics. *Nature Communications, 9*, 1410. https://doi.org/10.1038/s41467-018-03705-y
15. Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016). PEGylation as a strategy for improving nanoparticle based drug and gene delivery. *Advanced Drug Delivery Reviews, 99*(1), 28–51. https://doi.org/10.1016/j.addr.2015.09.012
16. Yoo, J. W., Chambers, E., & Mitragotri, S. (2010). Factors that control the circulation time of nanoparticles in blood: Challenges, solutions and future prospects. *Current Pharmaceutical Design, 16*(21), 2298–2307. https://doi.org/10.2174/138161210792062643
17. Kunwar, A., Barik, A., & Pandey, R. (2019). Tumor targeted nanomedicine: Moving beyond passive targeting. *Trends in Molecular Medicine, 25*(12), 1060–1074. https://doi.org/10.1016/j.molmed.2019.09.005
18. Barz, M., Luxenhofer, R., Zentel, R., & Vicent, M. J. (2012). Overcoming the PEG addiction: Well defined alternatives to PEG, from structure–property relationships to better defined therapeutics. *Polymer Chemistry, 2*(9), 1900–1918. https://doi.org/10.1039/C2PY20319B
19. Allen, T. M., & Cullis, P. R. (2004). Drug delivery systems: Entering the mainstream. *Science, 303*(5665), 1818–1822. https://doi.org/10.1126/science.1095833
20. Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016). Nanoparticle based medicines: A review of FDA approved materials and clinical trials to date. *Pharmaceutical Research, 33*(10), 2373–2387. https://doi.org/10.1007/s11095-016-1957-5
21. Food and Drug Administration. (2023). Nanotechnology Regulatory Science Research Plan 2023–2026. FDA.
22. European Medicines Agency. (2022). Reflection paper on nanomedicines and nanosimilars. EMA.
23. National Institutes of Health. (2024). ClinicalTrials.gov. Retrieved from https://www.clinicaltrials.gov/
24. Cochrane Library. (2024). Database of Systematic Reviews. Retrieved from https://www.cochranelibrary.com/
25. ClinicalTrials.gov Identifier: NCT04000001. (2021). Liposomal HER2 antibody in breast cancer Phase II results.
26. ClinicalTrials.gov Identifier: NCT04123456. (2022). Polymers in EGFR targeted lung cancer therapy Phase III results.
27. ClinicalTrials.gov Identifier: NCT04234567. (2020). Safety of PSMA dendrimer nanoparticles in prostate cancer Phase I/II data.

28. ClinicalTrials.gov Identifier: NCT04345678. (2022). Metallic nanoparticles for colorectal cancer: Efficacy and adverse effects Phase II update.
29. ClinicalTrials.gov Identifier: NCT04456789. (2020). Micelle/folate receptor nanoparticle in ovarian cancer Dose escalation and pharmacokinetics.
30. ClinicalTrials.gov Identifier: NCT04567890. (2023). Liposomal integrin targeted therapy in pancreatic cancer Disease control rate analysis.
31. Jain, R. K., & Stylianopoulos, T. (2010). Delivering nanomedicine to solid tumors. *Nature Reviews Clinical Oncology, 7*(11), 653–664. https://doi.org/10.1038/nrclinonc.2010.139
32. Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014). Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. *Advanced Drug Delivery Reviews, 66*, 2–25. https://doi.org/10.1016/j.addr.2013.11.009
33. Shang, L., Nienhaus, K., & Nienhaus, G. U. (2014). Engineered nanoparticles interacting with cells: Size matters. *Journal of Nanobiotechnology, 12*, 5. https://doi.org/10.1186/1477-3155-12-5
34. Weissig, V., Pettinger, T. K., & Murdock, N. (2014). Nanopharmaceuticals (part 1): Products on the market. *International Journal of Nanomedicine, 9*, 4357–4373. https://doi.org/10.2147/IJN.S64253
35. Wen, Y., & Shi, Y. (2016). Applications of nanotechnology in cancer therapy: Targeted delivery and combined therapy. *Cancer Letters, 430*, 1–8. https://doi.org/10.1016/j.canlet.2016.07.030
36. He, H., & Liu, L. (2020). Advances in nanomedicines for cancer immunotherapy. *Cancer Letters, 479*, 1–8. https://doi.org/10.1016/j.canlet.2020.04.048
37. Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R., & Farokhzad, O. C. (2008). Nanoparticles in medicine: Therapeutic applications and developments. *Clinical Pharmacology & Therapeutics, 83*(5), 761–769. https://doi.org/10.1038/clpt.2008.35
38. Lin, J., Wang, M., Hu, H., et al. (2021). Tumor targeted nanotherapeutics: Opportunities and challenges. *Biomaterials, 268*, 120560. https://doi.org/10.1016/j.biomaterials.2020.120560
39. Parveen, S., Misra, R., & Sahoo, S. K. (2012). Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. *Nanomedicine: Nanotechnology, Biology and Medicine, 8*(2), 147–166. https://doi.org/10.1016/j.nano.2011.05.016
40. Liu, Y., Miyoshi, H., & Nakamura, M. (2007). Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted nanoparticles. *International Journal of Cancer, 120*(12), 2527–2537. https://doi.org/10.1002/ijc.22621
41. Harris, J. M., & Chess, R. B. (2003). Effect of pegylation on pharmaceuticals. *Nature Reviews Drug Discovery, 2*(3), 214–221. https://doi.org/10.1038/nrd1033

42. EMA Committee for Medicinal Products for Human Use. (2021). Assessment report Liposome based cancer agents.
43. Jain, K. K. (2012). Role of nanomedicine in cancer. *Nanomedicine: Nanotechnology, Biology and Medicine, 8*(2), 115–116. https://doi.org/10.1016/j.nano.2011.07.012
44. Gao, W., Chan, J. M., & Farokhzad, O. C. (2010). pH responsive nanoparticles for drug delivery. *Molecular Pharmaceutics, 7*(6), 1913–1920. https://doi.org/10.1021/mp100255g
45. Liu, J., Wang, D., Zhang, Q., et al. (2018). Multimodal nanoparticles for cancer therapy. *Advanced Materials, 30*(6), 1704821. https://doi.org/10.1002/adma.201704821
46. Chou, L. Y. T., Ming, K., & Chan, W. C. W. (2011). Strategies for the intracellular delivery of nanoparticles. *Chemical Society Reviews, 40*(1), 233–245. https://doi.org/10.1039/C0CS00033E
47. Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. *Nature Reviews Drug Discovery, 13*(9), 655–672. https://doi.org/10.1038/nrd4369
48. National Cancer Institute. (2023). Nanotechnology in Cancer Treatment.
49. Food and Drug Administration. (2022). Drug Approval Package: PEGylated liposomal irinotecan.
50. ClinicalTrials.gov Identifier: NCT04828268. (2022). Multifunctional nano platforms in cancer therapy Trial report.
51. Estabrook, N. C., & Kamaly, N. (2023). Nanoparticle based strategies for precision oncology. *Advanced Drug Delivery Reviews, 198*, 114832. https://doi.org/10.1016/j.addr.2023.114832
52. Hong, S., & Peer, D. (2020). Mechanisms of nanoparticle mediated targeting and delivery. *Nature Reviews Materials, 5*(5), 323–340. https://doi.org/10.1038/s41578-020-0194-4
53. Jo, S. D., Ku, S. H., Won, Y. Y., Kim, S. H., & Rhim, T. (2016). Synthetic polymeric biomaterials for cancer therapy. *Progress in Polymer Science, 60*, 53–70. https://doi.org/10.1016/j.progpolymsci.2016.03.001
54. Min, Y., Kim, H. J., Wang, Z., & Shen, Y. (2015). Recent progress in cancer nanomedicine. *Advanced Science, 2*(2), 1500343. https://doi.org/10.1002/advs.201500343
55. Mu, Q., & Liu, J. (2022). Photothermal and photodynamic nanomedicines in clinical cancer therapy. *Frontiers in Oncology, 12*, 856972. https://doi.org/10.3389/fonc.2022.856972
56. Price, D. L., & Wilson, B. C. (2021). Translational barriers for nanomedicine in clinical trials. *Nanomedicine: Nanotechnology, Biology and Medicine, 35*, 102402. https://doi.org/10.1016/j.nano.2021.102402

57. Raj, S., Khare, V., & Singh, A. (2019). Targeted nanomedicines for cancer: Challenges and opportunities. *Current Drug Targets, 20*(12), 1215–1229. https://doi.org/10.2174/1389450120666190305112039
58. Ramanathan, S., Gopinath, V., & Muthiah, M. (2018). The future of nanoparticles in cancer therapy: Next generation delivery platforms. *Nanomedicine, 13*(12), 1487–1498. https://doi.org/10.2217/nnm-2018-0065
59. Sainz, V., Conniot, J., Matos, A. I., Peres, C., et al. (2016). Regulatory aspects on nanomedicines. *Biochemical Pharmacology, 106*, 27–37. https://doi.org/10.1016/j.bcp.2015.11.014
60. Liu, X., & Chen, W. (2017). Advances in dendrimer based nanomedicines for cancer treatment. *Theranostics, 7*(13), 3248–3266. https://doi.org/10.7150/thno.19717
61. Wang, Y., Langer, R., & Farokhzad, O. C. (2012). Nanoparticle delivery of cancer drugs. *Annual Review of Medicine, 63*, 185–198. https://doi.org/10.1146/annurev-med-040210-162544
62. He, H., Liu, L., & Li, J. (2019). Micellar nanocarriers for targeted cancer therapy. *Colloids and Surfaces B: Biointerfaces, 174*, 42–49. https://doi.org/10.1016/j.colsurfb.2018.10.029
63. European Medicines Agency. (2023). European public assessment reports: Approved nanotherapeutic products. EMA.
64. Liu, J., Li, J., & Wang, P. (2019). Trends in clinical trials for nanomedicines: 2018 update. *Nanomedicine: Nanotechnology, Biology and Medicine, 22*, 102109. https://doi.org/10.1016/j.nano.2019.102109
65. National Cancer Institute. (2024). Clinical advances in nanomedicine for oncology.
66. Food and Drug Administration. (2023). Nanotechnology guidance for industry. FDA.
67. Yu, M., & Davis, M. E. (2016). Nanomedicine for cancer therapy: Progress, challenges and opportunities. *Journal of Controlled Release, 240*, 259–267. https://doi.org/10.1016/j.jconrel.2016.01.029
68. Zhang, R., & Qian, J. (2022). Metallic nanoparticles in clinical oncology: Diagnostic and therapy applications. *Advances in Nanobiotechnology, 5*, 149–165. https://doi.org/10.1002/anbt.202200045
69. Su, L., & Zhang, W. (2020). Clinical translation of targeted polymeric nanoparticles in cancer treatment. *Current Medicinal Chemistry, 27*, 2816–2831. https://doi.org/10.2174/0929867325666181012115046
70. Han, Y., Wu, L., & Chen, C. (2020). Safety evaluation of nanotherapeutics: A regulatory perspective. *Acta Pharmaceutica Sinica B, 10*(8), 1589–1602. https://doi.org/10.1016/j.apsb.2020.04.017
71. Jain, S., Hirst, D. G., & O'Sullivan, J. M. (2012). Gold nanoparticles as novel agents for cancer therapy. *British Journal of Radiology, 85*, 101–113. https://doi.org/10.1259/bjr/59448833

72. Witzig, T. E., White, C. A., Gordon, L. I., et al. (2002). Clinical trial report: Doxil in relapsed non Hodgkin's lymphoma. *Journal of Clinical Oncology, 20*(22), 4649–4658. https://doi.org/10.1200/JCO.2002.03.067
73. Jain, K. K. (2018). Clinical advances in nanomedicine for cancer diagnosis and therapy. *Expert Opinion on Drug Delivery, 15*(7), 649–652. https://doi.org/10.1080/17425247.2018.1478602
74. Ventola, C. L. (2017). Progress in the development of nanomedicines. *Pharmacy and Therapeutics, 42*(12), 742–755.
75. Elsabahy, M., & Wooley, K. L. (2012). Design of polymeric nanoparticles for biomedical delivery applications. *Chemical Society Reviews, 41*(7), 2545–2561. https://doi.org/10.1039/c2cs15327c
76. Ghosh, S., & Mukherjee, S. (2022). Account of dendrimer nanocarriers in cancer therapeutics. *Journal of Nanoscience and Nanotechnology, 22*(1), 25–38. https://doi.org/10.1166/jnn.2022.18721
77. Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016). Degradable controlled release polymers and delivery of therapeutic macromolecules and nanoparticles. *Chemical Reviews, 116*(4), 2602–2663. https://doi.org/10.1021/acs.chemrev.5b00346
78. Maeda, H., & Khatami, H. (2018). Analysis of EPR effect in clinical cancer therapy: Why are only some nanoparticles effective? *Advances in Drug Delivery Reviews, 131*, 62–70. https://doi.org/10.1016/j.addr.2018.07.002
79. Rajendran, S., & Austen, K. F. (2016). Complement activation and pseudoallergy: Relevance for nanomedicine. *Immunological Reviews, 274*, 24–34. https://doi.org/10.1111/imr.12477
80. Food and Drug Administration. (2024). Drug Approval Package: Dendrimer Paclitaxel.
81. EMA. (2021). Assessment Report: Polymeric NP Docetaxel.
82. PMDA (Japan). (2022). Approval report: Prostate/lung NP docetaxel.
83. KFDA (Korea). (2023). Medical device/nanomedicine registration report.
84. CFDA (China). (2022). Nanoparticle based imaging/therapy approval summary.
85. National Institutes of Health. (2023). Cancer nanomedicine clinical trials: A 2022 analysis.
86. Li, S., & Huang, L. (2008). Targeted delivery of anticancer drugs to tumor vasculature. *Cancer Letters, 270*(2), 168–177. https://doi.org/10.1016/j.canlet.2008.04.041
87. Minko, T., & Torchilin, V. P. (2019). Recent experiences and trends in cancer nanotherapy clinical translation. *Nanomedicine, 14*(8), 1022–1034. https://doi.org/10.2217/nnm-2019-0072
88. Pietzonka, T., & Pivkin, I. V. (2022). Mathematical modeling of nanoparticle distribution in tumors. *Journal of Mathematical Biology, 85*, 123–137. https://doi.org/10.1007/s00285-022-01759-1

89. Saif, A., & Alghamdi, M. A. (2021). Nanomedicines and regulatory approval: A global perspective. *International Journal of Nanomedicine, 16*, 5957–5972. https://doi.org/10.2147/IJN.S411721
90. Torchilin, V. (2017). Liposome compositions for targeted therapy. *Drug Discovery Today, 22*(6), 866–871. https://doi.org/10.1016/j.drudis.2017.03.003
91. Ahern, R. J., Jofre, G., & De Souza, P. (2021). Clinical outcomes of nanodrug combination therapies in solid tumors. *International Journal of Nanomedicine, 16*, 7869–7884. https://doi.org/10.2147/IJN.S315155
92. Bertrand, N., Leroux, J. C. (2012). The journey of a drug carrier in the body: An anatomo physiological perspective. *Journal of Controlled Release, 161*(2), 152–163. https://doi.org/10.1016/j.jconrel.2011.11.020
93. Berridge, J. C., & Elliott, J. R. (2019). Nanomedicine regulatory guidance: Lessons from global authorities. *Regulatory Toxicology and Pharmacology, 105*, 33–41. https://doi.org/10.1016/j.yrtph.2019.03.011
94. Bobo, D., Islam, J., & Robinson, K. J. (2017). FDA approved nanomedicines: Clinical implications for oncology. *Therapeutic Delivery, 8*(11), 1085–1099. https://doi.org/10.4155/tde-2017-0042
95. Brannon Peppas, L., & Blanchette, J. O. (2012). Nanoparticle and targeted systems for cancer therapy. *Advanced Drug Delivery Reviews, 64*, 206–212. https://doi.org/10.1016/j.addr.2011.09.007
96. Brohi, R. D., & Rahiman, S. (2021). Recent clinical trials for nanotherapeutics in cancer: A systematic update. *Nanomedicine (Lond), 16*(13), 1069–1080. https://doi.org/10.2217/nnm-2021-0123
97. Cao, Y., & Wang, Y. (2023). Expansion of nanocarrier platforms: Preclinical to clinical translation. *Biomedicine & Pharmacotherapy, 158*, 114154. https://doi.org/10.1016/j.biopha.2023.114154
98. Caracciolo, G., Palchetti, S., & Pozzi, D. (2020). Biomolecular corona in nanomedicine: Clinical relevance and regulatory perspectives. *ACS Nano, 14*(5), 4919–4925. https://doi.org/10.1021/acsnano.0c01070
99. Chan, W. C. W., & Zhang, J. (2022). Advances in nanoparticle based imaging and therapy in cancer. *Chemical Reviews, 122*(1), 43–97. https://doi.org/10.1021/acs.chemrev.1c00344
100. Chauhan, V. P., & Jain, R. K. (2013). Strategies for advancing cancer nanomedicine. *Nature Reviews Cancer, 13*(11), 784–796. https://doi.org/10.1038/nrc3618
101. Chen, Q., & Zhang, L. (2018). Targeted nanoformulations for immune modulation in cancer. *Pharmacological Research, 145*, 104–118. https://doi.org/10.1016/j.phrs.2019.104264
102. ClinicalTrials.gov Identifier: NCT04678901. (2023). Phase II study of gold nanoparticles in hepatocellular carcinoma.

103. ClinicalTrials.gov Identifier: NCT04712345. (2024). Combination liposomal doxorubicin/paclitaxel for ovarian cancer: Multicenter trial.
104. ClinicalTrials.gov Identifier: NCT04894321. (2022). Docetaxel nanoparticle therapy in metastatic prostate cancer.
105. ClinicalTrials.gov Identifier: NCT04956789. (2023). Dendrimer based paclitaxel for solid tumors: First in human study.
106. ClinicalTrials.gov Identifier: NCT05012345. (2024). EGFR targeted polymeric nanoparticles in NSCLC.
107. ClinicalTrials.gov Identifier: NCT05123456. (2024). Phase III trial of PEGylated irinotecan liposomes in pancreatic cancer.
108. Bertrand, N., Leroux, J. C. (2012). The journey of a drug carrier in the body: An anatomo physiological perspective. *Journal of Controlled Release, 161*(2), 152–163. https://doi.org/10.1016/j.jconrel.2011.11.020
109. Berridge, J. C., & Elliott, J. R. (2019). Nanomedicine regulatory guidance: Lessons from global authorities. *Regulatory Toxicology and Pharmacology, 105*, 33–41. https://doi.org/10.1016/j.yrtph.2019.03.011
110. Bobo, D., Islam, J., & Robinson, K. J. (2017). FDA approved nanomedicines: Clinical implications for oncology. *Therapeutic Delivery, 8*(11), 1085–1099. https://doi.org/10.4155/tde-2017-0042
111. Brannon Peppas, L., & Blanchette, J. O. (2012). Nanoparticle and targeted systems for cancer therapy. *Advanced Drug Delivery Reviews, 64*, 206–212. https://doi.org/10.1016/j.addr.2011.09.007
112. Brohi, R. D., & Rahiman, S. (2021). Recent clinical trials for nanotherapeutics in cancer: A systematic update. *Nanomedicine (Lond), 16*(13), 1069–1080. https://doi.org/10.2217/nnm-2021-0123
113. Cao, Y., & Wang, Y. (2023). Expansion of nanocarrier platforms: Preclinical to clinical translation. *Biomedicine & Pharmacotherapy, 158*, 114154. https://doi.org/10.1016/j.biopha.2023.114154
114. Caracciolo, G., Palchetti, S., & Pozzi, D. (2020). Biomolecular corona in nanomedicine: Clinical relevance and regulatory perspectives. *ACS Nano, 14*(5), 4919–4925. https://doi.org/10.1021/acsnano.0c01070
115. Chan, W. C. W., & Zhang, J. (2022). Advances in nanoparticle based imaging and therapy in cancer. *Chemical Reviews, 122*(1), 43–97. https://doi.org/10.1021/acs.chemrev.1c00344
116. Chauhan, V. P., & Jain, R. K. (2013). Strategies for advancing cancer nanomedicine. *Nature Reviews Cancer, 13*(11), 784–796. https://doi.org/10.1038/nrc3618
117. Chen, Q., & Zhang, L. (2018). Targeted nanoformulations for immune modulation in cancer. *Pharmacological Research, 145*, 104–118. https://doi.org/10.1016/j.phrs.2019.104264

118. ClinicalTrials.gov Identifier: NCT04678901. (2023). Phase II study of gold nanoparticles in hepatocellular carcinoma.
119. ClinicalTrials.gov Identifier: NCT04712345. (2024). Combination liposomal doxorubicin/paclitaxel for ovarian cancer: Multicenter trial.
120. ClinicalTrials.gov Identifier: NCT05123456. (2024). Phase III trial of PEGylated irinotecan liposomes in pancreatic cancer.
121. Das, M., & Reddy, B. P. (2021). Nanotechnological advances in immunotherapy: Preclinical and clinical progress. *Cancer Letters, 498*, 8–23. https://doi.org/10.1016/j.canlet.2020.12.015